Emisphere's Oral Heparin Fails In Phase III Against Lovenox

Emisphere Technologies Inc. said Tuesday that its Phase III trial of oral heparin failed to show superiority to Aventis SA's injected Lovenox in preventing deep-vein thrombosis in patients undergoing total hip replacement surgery. (BioWorld Today)